Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | CD38 | P28907 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
| ▸ | MYC | P01106 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16018773 | 0.82 | MPO (0.40) | MPOP2RX7CD38AKR1B1ADORA2A | |
| SCHEMBL16016408 | 0.77 | MPO (0.42) | MPOP2RX7CD38AKR1B1ADORA2A | |
| SCHEMBL2656435 | 0.74 | HTT (0.51) | P2RX7LMNASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL16016416 | 0.73 | LMNA (0.47) | MPOLMNAGRM4SMN1; SMN2ALDH1A1 | |
| SCHEMBL16020969 | 0.72 | PTGER1 (0.40) | MPOP2RX7AKR1B1HPGD | |
| SCHEMBL16020965 | 0.71 | MPO (0.37) | MPOP2RX7CD38AKR1B1LMNA | |
| SCHEMBL16016327 | 0.70 | HRH4 (0.38) | MPOP2RX7ADORA2ASMN1; SMN2PDE2A | |
| SCHEMBL16016407 | 0.69 | MPO (0.38) | MPOP2RX7CD38AKR1B1LMNA | |
| SCHEMBL16016413 | 0.68 | HTT (0.37) | LMNASMN1; SMN2ALDH1A1HPGDHTT | |
| SCHEMBL16018768 | 0.68 | SLC6A3 (0.40) | MPOADORA2ALMNAGRM4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2774928-B1 | POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE-INHIBITING ACTIVITY | SHIONOGI & CO (JP) | 2017-08-30 | — | — | EP | disclosed |
| US-9200009-B2 | Polycyclic pyridone derivative having integrase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-20140256937-A1 | POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2014-09-11 | — | — | US | disclosed |
| EP-2774928-A1 | POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE-INHIBITING ACTIVITY | Shionogi & Co., Ltd. (JP) | 2014-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256937-A1 | POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE INHIBITORY ACTIVITY | TYMP, CDK6, IMPA1 | MPO 4689/4885P2RX7 1820/4885CD38 1632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.